The DOI matches its Crossref record; the references it cites are not checked yet.
NEUROBEHAVIORAL AND NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE
Abstract
Neuropsychiatric symptoms are common in Alzheimer's disease. Personality changes, mood disturbance, and psychosis are frequently seen and may coexist in the same patient. Neuropsychiatric symptoms may signal the onset of disease and often fluctuate and recur. These symptoms are associated with a more rapid cognitive and functional decline that can lead to institutionalization. Cholinergic therapy, disease-modifying therapy, and psychotropic medications can improve these symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Myelin defects and amyloid pathology seem to synergistically worsen behavioural deficits indicative of disinhibition.
“Myelin defects and amyloid pathology seem to synergistically worsen behavioural deficits indicative of disinhibition, which is a neuropsychiatric symptom that is also present in patients with AD22.”
From Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease (2023) · cites this paper as [22]
NPS in AD are marked by increasing incidence over time and by an episodic course.
“NPS in AD are marked by increasing incidence over time and by an episodic course.(4)”
Citations
The citation lists haven’t been fetched yet
References 95 · Cited by 174
Research works printed but not linked: 1
- Tariot, 1996, Treatment strategies for agitation and psychosis in dementia, J Clin Psychiatr, 57, 21
Metadata
- Authors
- Chung, J. A., & Cummings, J. L.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Neurologic Clinics
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 18
- Issue
- 4
- Pages
- 829-846
- ISSN
- 0733-8619 (ISSN-L)
- OpenAlex
- W1998764391
- Cited by
- 174
- References
- 95
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 2 · 2023: 7 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 9 · 2018: 8 · 2017: 8 · 2016: 5 · 2015: 4 · 2014: 12 · 2013: 10 · 2012: 10
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurologic Clinics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P50AG016570, AG 16570)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, neuropsychiatric symptoms, neurobehavioral symptoms, personality change, mood disturbance, psychosis, cognitive decline, functional decline, institutionalization, cholinergic therapy, disease-modifying therapy, psychotropic drugs
- MeSH terms
- Aged, Alzheimer Disease, Mental Disorders, Humans, Neuropsychological Tests, Psychotropic Drugs, Cholinergic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
